Results 31 to 40 of about 4,580 (188)

Nusinersen versus sham control in infantile-onset spinal muscular atrophy [PDF]

open access: yes, 2017
BACKGROUND: Spinal muscular atrophy is an autosomal recessive neuromuscular disorder that is caused by an insufficient level of survival motor neuron (SMN) protein.
Stein, S.   +564 more
core   +2 more sources

Implications of circulating neurofilamentsfor spinal muscular atrophytreatment early in life: A case series

open access: yesMolecular Therapy: Methods & Clinical Development, 2021
This longitudinal cohort study aimed to determine whether circulating neurofilaments (NFs) can monitor response to molecular therapies in newborns with spinal muscular atrophy (SMA; NCT02831296).
Christiano R.R. Alves   +13 more
doaj   +1 more source

Nusinersen in spinal muscular atrophy: Respiratory outcomes at tertiary care centers

open access: yesJournal of Nature and Science of Medicine, 2020
Objectives: The objective of the study wasto describe the effect of nusinersen therapy and its 1st-year associated outcomes, weaning of ventilator support, and length of stay in pediatric intensive care among ventilator-dependent spinal muscular atrophy (
Fahad Alsohime   +12 more
doaj   +1 more source

Comparison of Nusinersen and Evrysdi in the Treatment of Spinal Muscular Atrophy [PDF]

open access: yesE3S Web of Conferences, 2021
Spinal Muscular Atrophy (SMA) is a genetic neuromuscular disease that commonly affects children, and usually worsens with age that often leads to permanent disability and death for many of the SMA patients.
Zhu Xiaoying
doaj   +1 more source

Nusinersen: A Review in 5q Spinal Muscular Atrophy

open access: yes, 2021
DeclarationsFunding The preparation of this review was not supported by any external funding.Authorship and Conflict of interest Sheridan M. Hoy is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of ...
Sheridan M. Hoy (4897468)
core   +1 more source

The Antisense Oligonucleotide Nusinersen for Treatment of Spinal Muscular Atrophy [PDF]

open access: yes, 2021
Spinal muscular atrophy (SMA) is a rare, autosomal recessive neuromuscular degenerative disease characterized by loss of spinal cord motor neurons leading to progressive muscle wasting.
John W. Pruitt   +17 more
core   +1 more source

Proxy-Reported Quality of Life and Access to Nusinersen Among Patients with Spinal Muscular Atrophy in Saudi Arabia

open access: yesPatient Preference and Adherence, 2021
Yazed AlRuthia,1,2 Ghadah S Almuaythir,1 Hala H Alrasheed,1 Wejdan R Alsharif,1 Mohamad-Hani Temsah,3,4 Fahad Alsohime,3,4 Ibrahim Sales,1 Monira Alwhaibi,1 Fahad A Bashiri3,5 1Department of Clinical Pharmacy, College of Pharmacy, King Saud University ...
AlRuthia Y   +8 more
doaj  

Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study

open access: yesBMC Neurology, 2023
Background Spinal muscular atrophy (SMA) is a progressive degenerative neuromuscular disease. Nusinersen, with its quick onset of action, can benefit patients early in the treatment course.
Hua Yang   +7 more
doaj   +1 more source

Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients

open access: yesBrain Sciences, 2021
Approval of nusinersen, an intrathecally administered antisense oligonucleotide, for the treatment of 5q-spinal muscular atrophy (SMA) marked the beginning of a new therapeutic era in neurological diseases.
Lars Hendrik Müschen   +15 more
doaj   +1 more source

Clinical experience of nusinersen in a broad spectrum of spinal muscular atrophy: A retrospective study

open access: yesAnnals of Indian Academy of Neurology, 2020
Background: Nusinersen has recently been approved and more widely used as first-line treatment of spinal muscular atrophy (SMA). This study aimed to evaluate the real-world experience of nusinersen use for patients with a broad spectrum of SMA.
Ae Ryoung Kim   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy